Our scientists and engineers are developing a proprietary platform that genetically modifies healthy donor HSCs to remove select cell surface targets, making these HSCs and their progeny resistant to targeted therapies. This would enable targeted therapies to selectively destroy cancer cells while passing over healthy cells. Limiting on-target toxicity previously associated with targeted therapies may allow their use soon after Hematopoietic Stem Cell Transplant (HSCT), enabling new treatment opportunities for these patients. By combining our engineered HSCs with targeted therapies—including CAR-Ts, bispecific antibodies, and ADCs—we have the potential to completely replace the traditional standard of care for blood cancers such as AML.
Preclinical data supports the viability of this new approach, demonstrating cellular protection without compromising cell populations or function. We are committed to sharing with the scientific community the data that underscores our approach. In partnership with leading transplant centers across North America, we are engaging in a first in-human clinical trial for this breakthrough approach.